Thursday, November 9, 2017
Rockville biotech firm partners with Michael J. Fox Foundation on Parkinson's research effort
"We are pleased to have taken this step to make critical Parkinson's disease research tools more accessible to the wider research community," Dr. Zairen Sun, Vigene's CEO, said in a statement. "We believe that a key way to accelerate therapeutic development for Parkinson's patients is to provide validated viral vectors, that will enable researchers to obtain quality data, so that they focus on understanding the mechanisms underlying Parkinson's disease."